


Meet the Management 2023

Sports Medicine
29 November



Sports Medicine 10-year journey of growth



Strong revenue growth
Above market growth every year since 2019

Gaining share
Increased share by 7 points
2013 to 2022


Successful acquisitions
Strengthened the portfolio

Dedicated, specialised sales team
to accelerate growth in key markets

Leadership position in a large, attractive market




Global Sports Medicine market^[1], 2022



Global market size: ~\$5.5bn
2022 growth: +4%
2017-19 Avg growth: +5%

S+N Sports Medicine business^[2], 2022




A. Joint Repair **\$870M**
B. Arthroscopic Enabling Tech **\$567M**

Segment leadership positions




#1 in Arthroscopic Enabling Tech
#1 in Knee Repair
#1 in Hip Repair
#2 in Shoulder Repair

[1] Excludes Extremities & ENT, internal estimates. Calculation also excludes FASTSEAL, Service Revenue, Personal Protective Equipment
[2] S+N 2022 performance based on actuals



Restore
Enhancing healing

- + Restoring injuries/patients to full potential
- + A solid biologics platform for the future





Repair
Elevating standard-of-care in Joint Repair

- + Comprehensive procedural offering
- + Differentiated technologies



Enable
Increasing value of the arthroscopic tower

- + Expanded tower capabilities
- + Broadened procedure focus



Building intelligent arthroscopy



- + Intelligent integration of tower devices
- + Cloud technology to enhance planning, communication, and data integration

Changing Sports Medicine Surgery with Image-Based AI



- + Adding video-based navigation to the tower, with enhanced visualisation and mixed reality
- + More consistent patient outcomes, more efficient surgeon decision-making

Solutions that achieve new levels of precision, efficiency and patient outcomes

Increased accuracy

Consistent clinical outcomes

Efficient decision making

Personalised treatment



Restore **Enhancing Healing**

- + Restoring injuries/patients to full potential
- + A solid biologics platform for the future

Biologics



Repair **Elevating Standard-of-care in Joint Repair**

- + Comprehensive procedural offering
- + Differentiated technologies

Hip

Knee

Shoulder

Small Joint



Enable **Increasing Value of the Arthroscopic Tower**

- + Expanded tower capabilities
- + Broadened procedure focus

Video

Fluid Management

COBLATION

Arthroplasty Hemostasis

Mechanical Resection

Advanced Enabling Technologies

Patient Positioning

Strengthening leadership position in Knee Repair



Changing the standard of care to Meniscal Repair

- + Broad portfolio to address all types of meniscal tears
- + Accelerating the standard of care toward meniscal repair through medical education and clinical evidence
- + Launched FAST-FIX[◇] FLEX, the only device offering a bendable needle and shaft to access all zones of the meniscus

+ All tears all repairs Meniscal Repair Solutions



NOVOSTITCH PRO added to Meniscal portfolio through Ceterix acquisition in 2019

Innovation in Ligament Repair portfolio

+ Reimagine reconstruction Ligament Solutions



- + Procedure solutions to address the full spectrum of ligament pathologies and ACL knee injuries
- + 2023 launch of QUADTRAC[◇] System for minimally invasive quadriceps graft harvesting, to address surgeon graft needs

Entering Foot & Ankle Soft Tissue Repair segment



- + 2024 market entry with focused techniques and procedural kits
- + Portfolio addresses 90% of the soft tissue procedures in the segment
- + Core platform technology designed specifically for the Foot and Ankle surgeon
- + Significant opportunity to scale presence and share

Achilles Reconstruction

ULTRABRIDGE[◇] Adjustable Achilles Reconstruction Kit

FOOTPRINT[®] ULTRA
PK
Suture Anchor

HEALICOIL[®] PK
with Needles
Suture Anchor



Ankle Instability

ULTRABRACE[◇] Adjustable Ankle Instability Kit

FOOTPRINT[®] MINI PK
Suture Anchor

Q-FIX[®] ULTRA
All-Suture Anchor

Q-FIX[®] with Needles
All-Suture Anchor



REGENETEN[◇] use on the Achilles



**Insertional
Achilles
Reconstruction**




**Mid Substance
Achilles Repair**

Instability Excellence

Redefining peak performance

Solutions for the glenoid including soft tissue repairs, boney Bankart repairs and glenoid bone loss

+ Instability excellence
Redefining peak performance
Smith+Nephew




QFIX
All-Suture Anchor



MICRORAPTOR
REGENESORB
Suture Anchor



MICRORAPTOR Knotless
Suture Anchor



Glenoid Bone Loss
Advanced Instability System

Rotator Cuff Repair

Advanced healing solutions

Broad range of solutions to change the course of rotator cuff disease



HEALICOIL
REGENESORB
Suture Anchor




HEALICOIL KNOTLESS
Suture Anchor



REGENESORB
Material



REGENETEN
Bioinductive Implant



Restore
Enhancing Healing

- + Restoring injuries/patients to full potential
- + A solid biologics platform for the future

Biologics



Repair
Elevating Standard-of-care

- + Comprehensive procedural offering
- + Differentiated technologies

Hip

Knee

Shoulder

Small Joint



Enable
Increasing Value of the Arthroscopic Tower

- + Expanded tower capabilities
- + Broadened procedure focus

Video

Fluid Management

COBLATION

Arthroplasty Hemostasis

Mechanical Resection

Advanced Enabling Technologies

Patient Positioning

REGENETEN is redefining healing potential



A significant and costly problem ¹⁻³

- + Rotator cuff disease causes ongoing pain and limits patients' mobility⁴
- + Rotator cuff repairs amongst most common orthopedic surgeries⁵
- + Up to 2-in-5 rotator cuff repairs re-tear post-operatively⁶
- + Patients at risk of poor outcomes and revision surgery⁷

Changing the course of rotator cuff disease

- + REGENETEN stimulates the body's natural healing response to support new tendon growth and disrupt disease progression.^{1,2}
- + Implanted arthroscopically with the market-leading delivery system

Compelling clinical evidence

Clinical studies demonstrate:

- + Rapid recovery
- + Improved function
- + Reduced pain
- + Reduced re-tear rates
- + Enhanced quality of life⁸⁻¹²

Growing body of evidence

- + 6 randomised controlled trials in progress
- + 19 publications in peer-reviewed journals
- + Studied in over 1,800 patients across 13 countries

REGENETEN added to the portfolio through Rotation medical acquisition in 2017


1. Bokor DJ, Sonnabend D, Deady L et al. Evidence of healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a collagen implant: a 2-year MRI follow-up. *MLTJ*. 2016;6(1):16-25.
2. Washburn R, Anderson TM, Tokish JM. Arthroscopic rotator cuff augmentation: Surgical technique using bovine collagen bioinductive implant. *Arthroscopy Techniques*. 2017;6(2):e297-e301. 3. Mather RC, Koenig L, Acevedo D et al. The societal and economic value of rotator cuff repair. *J Bone Joint Surg Am*. 2013;95:1993-2000. 4. Lin JC, Weintraub N, Aragaki DR. Nonsurgical treatment for rotator cuff injury in the elderly. *Am Med Dir Assoc*. 2008;9(9):626-32. doi: 10.1016/j.jamda.2008.05.003.
5. Yanik EL, et al. *JSES Rev Rep Tech*. 2021;1(4):309-316. 6. Rashid MS, et al. *Acta Orthop*. 2017;88(6):606-611. 7. Yang J, et al. *Am J Sports Med*. 2017;45(3):733-741. 8. Ruiz Iban MA, et al. Presented at SECEC. 2022. 9. Bushnell BD, et al. *JSES Int*. 2021;5(2):228-237. 10. Thon SG, et al. *Am J Sports Med*. 2019;47(8):1901-1908. 11. Camacho-Chacon JA, et al. *J Exp Orthop*. 2022;9(1):53. 12. McIntyre L, et al. *Arthroscopy*. 2019 35(8):2262-2271.

Expanding REGENETEN market access

Roadmap for growth



- Leveraging clinical evidence to drive global market access
- Expanding indications and geographic penetration



Changing the paradigm in cartilage restoration



Agreement to acquire CartiHeal,
developer of novel Agili-C™ implant for
cartilage regeneration in knees

**Complementary to the Sports Medicine
Knee & Biologics portfolio**

**Leverages S+N expertise
in market development**

**Disruptive technology
with compelling evidence**

Agili-C implant is a first-in-class treatment for osteocondral (bone + cartilage) lesions, with FDA Premarket Approval

- Promotes natural regeneration of the articular cartilage, and restoration of its underlying subchondral bone
- Broader indication: includes patients with mild to moderate osteoarthritis, as well as the ~700,000 patients that receive cartilage repair annually in the US
- One-step, off-the-shelf surgical application
- Ready to use, no refrigeration or preparation required



Superior outcomes for patients, a better option for surgeons



Addresses a significant unmet need

Includes cartilage lesions in patients with mild to moderate osteoarthritis (OA)



- Often leads to pain and dysfunction
- Defects can deteriorate over time
- Limited treatment options available

Compelling evidence

Two-year randomised controlled trial¹
confirmed superiority of Agili-C implant over
current standard of care (SoC)²

- Statistically significant improvement of patient reported outcomes scores vs SoC
- Improved outcomes regardless of degree of OA, age group or lesion size
- Low surgical re-intervention

Sports Medicine, positioned for growth and leadership



**Proven Track
Record**



**Portfolio
Strength**



**Innovation
Pipeline**



**Commercial
Execution**



**Winning
Culture**



**Global
Presence**



Innovative pipeline to fuel growth



2023-2024 Launches driving growth

Shoulder

REGENETEN
Global Expansion



MICRORAPTOR◊
Knotless*



HEALICOIL◊
Knotless*



MINITAPE Proliferation



Q-FIX
Knotless



Knee

NOVOSTITCH◊
PRO*




FASTFIX◊
FLEX*



QUADTRAC*



ULTRABUTTON◊
Proliferation*



Agili-C**



Hip
Foot & Ankle

MICRORAPTOR RG
Suture Anchor*



CAP-FIX◊
Capsulotomy Blade*



CAP-FIX Capsule
Closure Device*



Foot & Ankle
Launches



Arthroscopic
Enabling
Technologies

WEREWOLF◊
FASTSEAL*



DOUBLEFLO◊
Inflow/Outflow Pump*



Platinum
Handpiece



INTELLIO◊
Connected Tower Solutions



INTELLIO
SHIFT



2025 and beyond



Biologics
& procedural
solutions



Extremities
expansion



Advanced
technologies
& navigation



Scott Schaffner

President, Sports Medicine

- More than 30 years of experience across the medical devices industry, including in sports medicine, cardiac rhythm management, neuromodulation, and spine
- Held a number of increasingly senior roles since joining S+N in 2014, and positions at Abbott Laboratories, Zimmer Biomet and ArthroCare prior to this
- MBA from Stanford University Graduate School of Business



Christie Van Geffen

SVP, Global Marketing, Sports Medicine

- Over 20 years of experience in sports medicine
- Held a range of progressively senior roles at S+N, including as Shoulder Market Manager for the UK, Ireland and Nordics region, and SVP, Global Marketing – Joint Repair
- Strong track record of developing and marketing innovative technologies, and integral in the acquisition and integration of several impactful technologies, including REGENETEN



Smith+Nephew